JPWO2021029430A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021029430A5 JPWO2021029430A5 JP2021539312A JP2021539312A JPWO2021029430A5 JP WO2021029430 A5 JPWO2021029430 A5 JP WO2021029430A5 JP 2021539312 A JP2021539312 A JP 2021539312A JP 2021539312 A JP2021539312 A JP 2021539312A JP WO2021029430 A5 JPWO2021029430 A5 JP WO2021029430A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- composition according
- benzo
- quinoline
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 3
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 3
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 3
- REOHQDNGVJIIPS-WLHGVMLRSA-N 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 REOHQDNGVJIIPS-WLHGVMLRSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000018460 Feeding disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150733A JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/031895 WO2021029020A1 (ja) | 2019-08-13 | 2019-08-13 | 経口医薬組成物 |
| JPPCT/JP2019/031895 | 2019-08-13 | ||
| PCT/JP2020/030777 WO2021029430A1 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150733A Division JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021029430A1 JPWO2021029430A1 (https=) | 2021-02-18 |
| JPWO2021029430A5 true JPWO2021029430A5 (https=) | 2022-06-22 |
| JP7148733B2 JP7148733B2 (ja) | 2022-10-05 |
Family
ID=74569440
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539751A Withdrawn JPWO2021029020A1 (https=) | 2019-08-13 | 2019-08-13 | |
| JP2021539311A Active JP7110495B2 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
| JP2021539312A Active JP7148733B2 (ja) | 2019-08-13 | 2020-08-13 | 複素環化合物を含有する経口医薬組成物 |
| JP2022112389A Pending JP2022132411A (ja) | 2019-08-13 | 2022-07-13 | 経口医薬組成物 |
| JP2022150733A Active JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A Pending JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
| JP2025027501A Pending JP2025074104A (ja) | 2019-08-13 | 2025-02-25 | 経口医薬組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539751A Withdrawn JPWO2021029020A1 (https=) | 2019-08-13 | 2019-08-13 | |
| JP2021539311A Active JP7110495B2 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112389A Pending JP2022132411A (ja) | 2019-08-13 | 2022-07-13 | 経口医薬組成物 |
| JP2022150733A Active JP7635187B2 (ja) | 2019-08-13 | 2022-09-21 | 複素環化合物を含有する経口医薬組成物 |
| JP2025020427A Pending JP2025072595A (ja) | 2019-08-13 | 2025-02-12 | 複素環化合物を含有する経口医薬組成物 |
| JP2025027501A Pending JP2025074104A (ja) | 2019-08-13 | 2025-02-25 | 経口医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220273647A1 (https=) |
| EP (2) | EP4015001A4 (https=) |
| JP (7) | JPWO2021029020A1 (https=) |
| KR (2) | KR20220046625A (https=) |
| CN (2) | CN114222562A (https=) |
| AU (2) | AU2020328351B2 (https=) |
| BR (2) | BR112022002433A2 (https=) |
| CA (2) | CA3150751A1 (https=) |
| IL (2) | IL290469B2 (https=) |
| MX (3) | MX2022001758A (https=) |
| MY (2) | MY208261A (https=) |
| PH (2) | PH12022550347A1 (https=) |
| TW (2) | TWI870441B (https=) |
| WO (3) | WO2021029020A1 (https=) |
| ZA (2) | ZA202202319B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
| CN118742293A (zh) * | 2022-01-31 | 2024-10-01 | 住友精化株式会社 | 药物控释制剂用组合物和药物控释制剂 |
| JP2023173950A (ja) * | 2022-05-27 | 2023-12-07 | 同仁医薬化工株式会社 | 経口液剤 |
| AU2024247059A1 (en) * | 2023-03-29 | 2025-10-30 | Merck Sharp & Dohme (Uk) Limited | Controlled release pde10a formulations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (https=) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| TWI632921B (zh) * | 2011-10-19 | 2018-08-21 | 大塚製藥股份有限公司 | 口服溶液 |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| EP2911670A1 (en) * | 2012-10-25 | 2015-09-02 | Otsuka Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
| CN106667969A (zh) * | 2017-02-23 | 2017-05-17 | 佛山市弘泰药物研发有限公司 | 一种依匹哌唑缓释胶囊及其制备方法 |
| JP6886654B2 (ja) | 2017-04-11 | 2021-06-16 | 学校法人帝京大学 | 抗カンジダ活性組成物 |
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
-
2019
- 2019-08-13 WO PCT/JP2019/031895 patent/WO2021029020A1/ja not_active Ceased
- 2019-08-13 JP JP2021539751A patent/JPWO2021029020A1/ja not_active Withdrawn
-
2020
- 2020-08-13 WO PCT/JP2020/030777 patent/WO2021029430A1/ja not_active Ceased
- 2020-08-13 EP EP20853189.7A patent/EP4015001A4/en active Pending
- 2020-08-13 AU AU2020328351A patent/AU2020328351B2/en active Active
- 2020-08-13 MY MYPI2022000768A patent/MY208261A/en unknown
- 2020-08-13 PH PH1/2022/550347A patent/PH12022550347A1/en unknown
- 2020-08-13 KR KR1020227007745A patent/KR20220046625A/ko active Pending
- 2020-08-13 US US17/634,758 patent/US20220273647A1/en not_active Abandoned
- 2020-08-13 CA CA3150751A patent/CA3150751A1/en active Pending
- 2020-08-13 US US17/634,791 patent/US20220280418A1/en not_active Abandoned
- 2020-08-13 CN CN202080056803.2A patent/CN114222562A/zh active Pending
- 2020-08-13 JP JP2021539311A patent/JP7110495B2/ja active Active
- 2020-08-13 WO PCT/JP2020/030776 patent/WO2021029429A1/ja not_active Ceased
- 2020-08-13 TW TW109127608A patent/TWI870441B/zh active
- 2020-08-13 BR BR112022002433A patent/BR112022002433A2/pt unknown
- 2020-08-13 IL IL290469A patent/IL290469B2/en unknown
- 2020-08-13 CN CN202080056806.6A patent/CN114222575A/zh active Pending
- 2020-08-13 BR BR112022002436A patent/BR112022002436A2/pt unknown
- 2020-08-13 PH PH1/2022/550349A patent/PH12022550349B1/en unknown
- 2020-08-13 KR KR1020227007743A patent/KR20220046624A/ko active Pending
- 2020-08-13 JP JP2021539312A patent/JP7148733B2/ja active Active
- 2020-08-13 CA CA3150827A patent/CA3150827A1/en active Pending
- 2020-08-13 TW TW109127609A patent/TWI870442B/zh active
- 2020-08-13 MY MYPI2022000781A patent/MY208267A/en unknown
- 2020-08-13 AU AU2020327792A patent/AU2020327792B2/en active Active
- 2020-08-13 MX MX2022001758A patent/MX2022001758A/es unknown
- 2020-08-13 EP EP20853069.1A patent/EP4015002A4/en active Pending
- 2020-08-13 MX MX2022001759A patent/MX2022001759A/es unknown
-
2022
- 2022-02-09 IL IL290472A patent/IL290472A/en unknown
- 2022-02-10 MX MX2025006039A patent/MX2025006039A/es unknown
- 2022-02-23 ZA ZA2022/02319A patent/ZA202202319B/en unknown
- 2022-02-23 ZA ZA2022/02320A patent/ZA202202320B/en unknown
- 2022-07-13 JP JP2022112389A patent/JP2022132411A/ja active Pending
- 2022-09-21 JP JP2022150733A patent/JP7635187B2/ja active Active
-
2024
- 2024-08-26 US US18/815,060 patent/US20250127776A1/en active Pending
- 2024-09-18 US US18/888,277 patent/US20250057835A1/en active Pending
-
2025
- 2025-02-12 JP JP2025020427A patent/JP2025072595A/ja active Pending
- 2025-02-25 JP JP2025027501A patent/JP2025074104A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021029430A5 (https=) | ||
| JP2022180531A5 (https=) | ||
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| Masters et al. | Melatonin, the hormone of darkness: from sleep promotion to ebola treatment | |
| Raeder et al. | Rotigotine transdermal patch for motor and non-motor Parkinson’s disease: A review of 12 years’ clinical experience | |
| Mizuno et al. | Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease | |
| Wine et al. | Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions | |
| JPWO2021029429A5 (https=) | ||
| Joseph-Vanderpool et al. | Seasonal variation in behavioral responses to m-CPP in patients with seasonal affective disorder and controls | |
| JP2003503450A5 (https=) | ||
| Korani et al. | Parenteral systems for statin delivery: a review | |
| Raybuck et al. | Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. | |
| Roux et al. | Medication effects on sleep | |
| Manconi et al. | Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome | |
| Cass et al. | Protection by GDNF and other trophic factors against the dopamine‐depleting effects of neurotoxic doses of methamphetamine | |
| Neubauer | The evolution and development of insomnia pharmacotherapies | |
| Castaneda et al. | A review of the effects of moderate alcohol intake on psychiatric and sleep disorders | |
| Chen et al. | Preparation of aripiprazole-poly (methyl vinyl ether-co-maleic anhydride) nanocomposites via supercritical antisolvent process for improved antidepression therapy | |
| Im et al. | Management of sleep disorders in stroke | |
| Paterson et al. | The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat | |
| Wong et al. | A non-pharmacological intervention for insomnia: tryptophan-fructooligosaccharides combination improves sleep in mice via anti-inflammation and gut microbiota modulation | |
| CN1111408C (zh) | 药物滥用疾病治疗中的吡啶基－和嘧啶基－哌嗪类化合物 | |
| Thomsen et al. | The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases. | |
| WO2023230303A1 (en) | Treatment of cognitive decline related to anesthesia and sedation | |
| CN103814968A (zh) | 一种用于麻醉手术室杀菌的药剂 |